Loading...

Neurocrine Biosciences, Inc.

NBIXNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$126.75
$-1.03(-0.81%)

Neurocrine Biosciences, Inc. NBIX Peers

See (NBIX) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NBIX$126.75-0.81%12.5B42.96$2.95N/A
ZTS$156.69-0.34%69.4B28.02$5.56+1.20%
TAK$15.12+0.97%47.4B65.52$0.23+3.91%
HLN$10.39-1.10%46.9B24.24$0.43+1.12%
TEVA$16.80-1.18%19B-14.42-$1.15N/A
ITCI$131.87+0.00%14B-180.64-$0.73N/A
RDY$15.03-3.03%12.8B19.65$0.78+0.62%
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
VTRS$9.14+2.76%10.7B-2.87-$3.18+5.29%
RGC$18.21-16.20%10B-2019.00-$0.01N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NBIX vs ZTS Comparison

NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 12.5B. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, NBIX is priced at $126.75, while ZTS trades at $156.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 42.96, whereas ZTS's P/E ratio is 28.02. In terms of profitability, NBIX's ROE is +0.12%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, NBIX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.

Stock Price Comparison

Loading...

Frequently Asked Questions

;